Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Citigroup
Citigroup upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a neutral rating to a buy rating in a report released on Wednesday, Marketbeat.com reports. The brokerage currently has $700.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $600.00. A number of other analysts also recently weighed in […]
Citigroup upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a neutral rating to a buy rating in a report released on Wednesday, Marketbeat.com reports. The brokerage currently has $700.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $600.00. A number of other analysts also recently weighed in […]
